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Background: To evaluate the safety of combination vaccine treatment of multiple peptides, phase I clinical trial
was conducted for patients with advanced colorectal cancer using five novel HLA-A*2402-restricted peptides, three
peptides derived from oncoantigens, ring finger protein 43 (RNF43), 34 kDa-translocase of the outer mitochondrial
membrane (TOMM34), and insulin-like growth factor–II mRNA binding protein 3 (KOC1), and the remaining two
from angiogenesis factors, vascular endothelial growth factor receptor 1 (VEGFR1) and VEGFR2.
Methods: Eighteen HLA- A*2402-positive colorectal cancer patients who had failed to standard therapy were enrolled
in this study. 0.5 mg, 1.0 mg or 3.0 mg each of the peptides was mixed with incomplete Freund’s adjuvant and
then subcutaneously injected at five separated sites once a week. We also examined possible effect of a single site
injection of “the cocktail of 5 peptides” on the immunological responses. ELISPOT assay was performed before and
after vaccinations in the schedule of every 4 weeks.
Results: The vaccine treatment using multiple peptides was well tolerated without any severe treatment-associated
systemic adverse events. Dose-dependent induction of peptide-specific cytotoxic T lymphocytes was observed. The
single injection of “peptides cocktail” did not diminish the immunological responses. Regarding the clinical outcome,
one patient achieved complete response and 6 patients revealed stable disease for 4 to 7 months. The median overall
survival time (MST) was 13.5 months. Patients, in which we detected induction of cytotoxic T lymphocytes specific to 3
or more peptides, revealed significantly better prognosis (MST; 27.8 months) than those with poorer immune responses
(MST; 3.7 months) (p = 0.032).
Conclusion: Our cancer vaccine treatment using multiple peptides is a promising approach for advanced colorectal
cancer with the minimum risk of systemic adverse reactions.
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Colorectal cancer (CRC) is the third most common can-
cer and the second leading cause of cancer-related death
in industrialized countries [1]. In the last decade, the
combined regimens of multiple anticancer drugs have
been applied and markedly improved the survival of pa-
tients with CRC at stages III and IV [2]. However, many
patients often face to progression of the diseases due to
chemo-resistance.
Recent development in genome-based technologies has
enabled us to obtain comprehensive gene expression pro-
files of malignant cells compared with normal cells [3]. By
applying cDNA microarray technology coupled with laser
micro-dissection, we had identified three oncoantigens,
ring finger protein 43 (RNF43) [4], 34 kDa-translocase of
the outer mitochondrial membrane (TOMM34) [5], and
KOC1 (IMP-3; IGF-II mRNA binding protein 3) [6,7], as
targets for development of cancer peptide vaccines for
CRC. An oncoantigen was defined as a molecule with high
immunogenicity in our immune system and with onco-
genic function that plays a critical role in the growth of
tumor cells. Since the oncoantigen is essential for the cell
growth, the probability of immune escape of cancer cells
by reducing or lacking these proteins is expected to be
low [8,9]. In addition, these three molecules are specific-
ally expressed in cancer cells, the risk of autoimmune re-
actions by vaccine treatment using the peptides derived
from these proteins is expected to be minimum [4-6].
Although immunotherapy using tumor infiltrating cells
(TIL) or vaccine treatment have been expected as a prom-
ising modality to treat cancer, recent reports have indi-
cated several mechanisms in tumor tissues to protect
cancer cells from immune attacks [10]. For example, the
limitation of antitumor effects of cytotoxic T lymphocytes
(CTL) was explained by tumor cell heterogeneity; a subset
of tumor cells revealed downregulation or loss of expres-
sions of human leukocyte antigen (HLA) or targeted anti-
gen proteins [11,12]. The growth of solid neoplasms
always accompanies with neovascularization [13] which
is associated with the expression of vascular endothelial
growth factor receptor 1 (VEGFR1) [14] and VEGFR2
[15]. These two molecules were highly expressed in tumor
vascular endothelial cells. Hence, our vaccine treatment
including the peptides derived from VEGFR1 and VEGFR2
is also able to target neovascular endothelial cells, suppress
neovascurization, and then reduce the energy and oxygen
supply into the tumor tissues.
In this study, since an HLA-A*2402 allele is the most
common HLA-A allele in the Japanese population with
the allelic frequency of approximately 60% [16], we se-
lected five HLA-A*2402-restricted peptides derived from
RNF43, TOMM34, KOC1, VEGFR1, and VEGFR2 for
the clinical trial. The purpose of this study was to evalu-
ate the safety and biological responses of these fivepeptides. Additionally, we compared the immunological
responses of the separate injections of each of five pep-
tides with those of the single injection of a cocktail of
five peptides. We here demonstrate the safety of these
peptides and a promising result of our cocktail treatment
of five peptides for the improvement of prognosis of ad-
vanced CRC.
Patients and methods
Patients and eligibility criteria
The study protocol was approved by the Institutional
Ethics Review Boards of Yamaguchi University (H18-82),
was carried out in accordance with the Helsinki declar-
ation on experimentation on human subjects, and was
registered in the UMIN Clinical Trials Registry as
UMIN000004948. Written informed consent was ob-
tained from the patients at the time of enrollment. Pa-
tients were eligible for enrollment (1) when they had
histologically confirmed CRC without indication of sur-
gical resection, (2) when they had failed to respond to
prior standard chemotherapy or were intolerable to the
standard therapy, and (3) when they were HLA-A*2402-
positive by DNA typing. We monitored for at least
4 weeks from the termination of the prior treatment to
the beginning of the vaccine treatment, in order to wait
patients’ full recovery from adverse events with grade 3
or higher according to the Common Terminology
Criteria for Adverse Events version3.0 (CTCAE). The
patients were required to have an Eastern Cooperative
Oncology Group performance status (PS) of 0 to 2, to
be older than 20 years of age and to have a life expect-
ancy of at least 3 months. Adequate bone marrow
function (white blood cell count ≥2,000/mm3 and plate-
let count ≥75,000/mm3), renal function (serum creatin-
ine ≤2.0 mg/dl) and liver function (transaminase within
3.0 times the institution's upper limit of normal) were
required. Patients were excluded if they were pregnant,
had severe ischemic heart disease, had active infectious
disease, had any steroid-dependent autoimmune dis-
eases, or had any prior peptide vaccination therapies.
Peptides
The RNF43-721 (NSQPVWLCL) [17], TOMM34-299
(KLRQEVKQNL) [5], KOC1(IMP-3)-508 (KTVNELQNL)
[18], VEGFR1-1084 (SYGVLLWEI) [19] and VEGFR2-169
(RFVPDGNRI) [20] peptides restricted with HLA-A*2402
were synthesized by American Peptide Company Inc.
(Sunnyvale, CA, USA) according to a standard solid-phase
synthesis method and purified by reverse-phase high
performance liquid chromatography (HPLC). The purity
(>95%) and the identity of the peptides were determined
by analytical HPLC and mass spectrometry analysis,
respectively. Endotoxin levels and the bio-burden of
these peptides were tested and determined to be within
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vaccines. These peptides and the epitope peptide derived
from the human immunodeficiency virus-envelope (HIV-
Env) protein restricted with HLA-A*2402 (RYLRDQQLL)
were used to measure the CTL response.
Study design and End-points
Study 1
This study was a phase I clinical trial with dose-escalation
of the five peptides. This study was primarily conducted to
evaluate the safety and to find the recommended dose
(RD) of these peptides, and secondarily to evaluate im-
munological and antitumor effects. Dose escalation was
performed in 3 patients’ cohort with doses of 0.5 mg, 1 mg,
and 3 mg for each peptide. Each peptide was mixed with
0.5 ml of incomplete Freund's adjuvant (IFA) (Montanide
ISA51; Seppic, Paris, France) administered to patients.
Study 2
Since the theoretical binding affinities of the 5 epitope
peptides to HLA-A*2402 were not so different (Table 1),
within one order, a single injection of the cocktail of five
peptides could be expected to induce immune responses
at the same level as separate injections of each of the five
peptides. This study was conducted to evaluate the
safety as well as immunological and antitumor effects.
The cocktail of 5 peptides at the dose of 3 mg was mixed
with 1.5 ml of IFA and administered to 6 patients.
Study 1 & 2
The peptides were administered subcutaneously into the
thigh or axilla regions on days 1, 8, 15, and 22 in a 28-day
treatment course. Administration of the peptides was per-
formed repeatedly for at least eight weeks for the evalu-
ation of the safety. Vaccination was continued after
8 weeks or even after the progression of the disease when
a patient wished and a primary doctor who provided best
supportive care or additional chemotherapies, recom-
mended. From the fourth courses of treatment, the vac-
cination schedule was changed to be biweekly, and from
the seven courses, it was reduced to once a month.
A complete blood count and serum chemistry tests were
performed every 2 weeks. Signs of toxicity were assessedTable 1 Binding score of each peptide




RNF43 - 721 NSQPVWLCL 10 90%
TOMM34 - 299 KLRQEVKQNL 13.4 80%
KOC1 - 508 KTVNELQNL 14.4 77%
VEGFR1 - 1084 SYGVLLWEI 66 100%**
VEGFR2 - 169 RFVPDGNRI 22
*The binding affinities were estimated using the BioInformatics and Molecular Anal
**100% in tumor cells as well as tumor associated neovascularity.according to CTCAE. Dose-limiting toxicity was defined
as a hematological toxicity of grade 4 or greater and non-
hematological toxicity of grade 3 or greater. Fifty milliliters
of blood was drawn before each course, and then
peripheral-blood mononuclear cells (PBMCs) and blood
plasma were isolated. PBMCs and plasma were preserved
in liquid nitrogen tank until examination. The vaccinated
patients (n = 18) were assessed for immunological and
clinical responses according to the Response Evaluation
Criteria in Solid Tumors version1.0 (RECIST) as well as
serum Carcinoembryonic antigen (CEA). All known sites
of disease were evaluated on a monthly basis by computed
tomography (CT) or magnetic resonance imaging (MRI)
before vaccination and after each course.
Estimation of local skin reactions at the vaccinated sites
Local skin reactions at injected site of vaccine were
assessed according to CTCAE grading.
Measurement of the peptide-specific IFN-γ response
Antigen-specific T cell response was estimated by
enzyme-linked ImmunoSpot (ELISPOT) assays following
in vitro sensitization as described previously [21,22]. The
number of peptide-specific spots was calculated by sub-
tracting the spot number in the control well from the
spot number of a well with vaccinated peptide-pulsed
stimulator cells. Antigen specific T cell response was
classified into four grades (−, +, ++, or +++) according
to the algorithm flow chart described in our previous re-
port (+++: IFN-γ producing cell is contained more than
0.2%, ++: 0.02 - 0.2%, +: 0.01 - 0.02%, −: less than 0.01%
in the sample applied for ELISPOT) (Additional file 1:
Figure S1 [21]). Sensitivity of our ELISPOT assay was es-
timated at approximately average level by the ELISPOT
panel of the Cancer Immunotherapy Consortium [23].
Statistical analysis
Overall survival (OS) rates and progression free survival
(PFS) rates were analyzed by the Kaplan-Meier method,
and survival was measured in days from the first vaccin-
ation to succumbing to the disease. P-values were assessed
using a log-rank test. Cox regression model was used for





Growth of cancer cells [4,17]
Growth of cancer cells [5]
Metastasis and invasion [6,7,18]
Tumor angiogenesis,growth through autocrine [14,15,19,20]
ysis Section websites.
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cific immune responses. All statistical analyses were per-
formed with SPSS statistics 17.0 (SPSS, Chicago, IL, USA).
P < 0.05 was considered statistically significant.
Results
From February 2007 to March 2009, nineteen CRC pa-
tients were enrolled in this study and received vaccine
treatment. One patient (case 7) who refused continuation
of the vaccine therapy after a single administration of pep-
tides was excluded from this analysis. Characteristics of
eighteen patients are summarized in Table 2. Most of the
patients except two cases had received chemotherapy regi-
mens including fluorouracil, irinotecan or oxaliplatin prior
to the vaccine treatment; one (case 11) of the two excep-
tions was due to pelvic abscess after the low anterior re-
section. The other exception (case 16) was because this
patient refused chemotherapy. Another patient (case 18)
had refused surgical treatment because she was afraid of
the high complication risk of the second operation of the
recurrent tumor in the pelvis. We provided vaccination
with the written informed consent, but she accepted to re-
ceive curative resection after 8 weeks of vaccination. This
case was included in the immunological analysis, but ex-
cluded from the analysis of survival.
Study 1: dose escalation study
Safety, peptides-specific immune responses and
recommended dose
The vaccination was well tolerated without any high-
grade systemic adverse reactions in any of the 19
patients at any doses as shown in Table 2. However, all
patients revealed injection site reactions with grade 1–2
swelling with/without inflammation except two cases
with grade 2 ulceration. In this cohort of 19 patients, no
dose-limiting toxicity was detected in any patients.
ELISPOT assay (Additional file 2: Figure S2) was per-
formed using the samples obtained before and every
4 weeks after the beginning of vaccinations to evaluate in-
duction of peptide specific CTL by measuring the IFN-γ
secretion as biomarkers. The average numbers of specific
CTL induction against each of five peptides per each pa-
tient within 12 vaccinations (3 courses) at the doses of
0.5 mg, 1.0 mg, and 3.0 mg were 2.0 (6 peptides/3 patients),
2.3 (7/3), and 3.2 (19/6), respectively (Table 3). The CTL
responses within 3 courses (12 weeks) of vaccinations were
highest in the group who received the dosage of 3.0 mg.
We therefore decided that the RD was 3.0 mg/body.
Study 2: peptide cocktail study
Safety and peptides specific IFN-γ response
Since the weekly injection at five independent loci for
each peptide is painful to patients and the binding affin-
ities of these 5 epitope peptides to the HLA moleculeswere suspected to be not so different (Table 1), we ex-
amined whether the mixture of five peptides in one shot
(cocktail peptide) can induce peptide-specific CTLs at
same or similar levels, compared with the five independ-
ent shots of each peptide. The cocktail of 3 mg each of 5
peptides was mixed with IFA and tested in 6 patients.
This vaccination protocol was well tolerated without
any treatment-associated adverse events except the grade
1 or 2 injection site reaction. We measured peptide-
specific CTL responses in these cocktail-treated patients
and compared with those in patients who received injec-
tion at five independent loci (Table 3). In six “cocktail”-
treated patients, we observed induction of CTLs in 5
patients for RNF43, 3 patients for TOMM34, 4 patients
for KOC1, 4 patients for VEGFR1, and 5 patients for
VEGFR2 (total of 21 peptide-specific CTL inductions in
6 patients) within 3 courses of the vaccination. Among
the patients who were injected 3 mg each of the five
peptides independently revealed induction of CTLs for
RFN43, TOMM34, KOC1, VEGFR1, and VEGFR2 in 3,
4, 5, 4, and 3 patients, respectively (total of 19 peptide-
specific CTL inductions in 6 patients). There was no
significant difference to induce the immune responses
between the multiple injections of “each peptide” and
the single injection of “the peptide cocktail” (p = 0.694,
t-test). These results indicated that the single injection
of “the peptide cocktail” is likely to induce the similar
immune responses to the multiple injections of “each
peptide”.
Clinical evaluation
One patient (case 1) achieved a complete response in
lymph node metastasis in the hepato-duodenal ligament
and lasted for over 5 years (Figure 1A&B). In addition, 6
patients maintained stable disease condition for 4 to
7 months. In case 3, the massive liver metastases as well
as lung metastases (data not shown) were kept stably for
5 months as shown in Figure 1C.
Survival
Median PFS and OS periods of the 17 patients were
2.3 months (95% CI: 2.0-2.6) and 13.5 months (95% CI:
1.4-25.6), respectively (Figure 2A). The 2-year survival
rate was 41.2% (95% CI: 17.9-64.5). Significant improve-
ment of OS after 6 months from the first vaccination
has implied the delayed response of the vaccination [24].
Patients with strong induration and redness, or those
with ulceration (CTCAE grade2) survived significantly
longer than patients without these reactions (Figure 2B).
Patients with CTL responses to two or more peptides
within 3 courses of the vaccination trended to have a
longer survival (Figure 2C). Patients who revealed posi-
tive CTL responses against three or more peptides
within 6 courses (24 weeks) of the vaccination showed























Within 3 courses of vaccinations
Within 6 courses of vaccinations
1 0.5 56 M 0 LN IRI, OX, FU ++ – – – – 85 2150 2 None CR 2150 2150 A None
– – + ++ –
+ ++ + ++ –
2 0.5 72 F 1 Lung, bone IRI, OX, FU – – – – – 16 120 1 None PD 60 191 D None
+ – – – +
+ + – – +
3 0.5 75 M 1 Liver, lung IRI, OX, FU – – ++ – – 27 364 1 None SD 158 406 D OX, FU, BEV
++ – – – +
++ – + – +
4 1 59 F 2 Dissemi. IRI, OX, FU – – – – – 8 49 1 None PD 36 80 D None
++ – – – –
++ – + – +
5 1 68 M 0 Lung IRI, OX, FU – – – – – 25 329 2 None PD 68 1009 D OX, FU, IRI,
BEV, CETU
++ + ++ + ++
++ + ++ + ++
6 1 69 M 2 Lung, LN IRI, OX, FU – – + – – 13 84 2 None PD 62 110 D None
– ++ – – –
– ++ – – –
8 3 85 F 1 Dissemi. FU – – – – – 11 70 2 None PD 103 461 D IRI, FU
– – – + –
– – – + –
9 3 59 M 0 Lung IRI, OX, FU + – – – – 45 777 2 None SD 221 885 D None
++ ++ ++ ++ –
++ ++ ++ ++ –
10 3 49 F 0 Liver, lung IRI, FU ++ – – – – 39 777 2 Fever <38.0°C PD 69 834 D OX, FU,
IRI, BEV
+++ – ++ ++ +



















Table 2 Patients characteristics and outcomes (Continued)
11 3 46 F 0 Lung none – – – – – 13 64 2 Erythena (G1) SD 117 1029 D OX, FU,
IRI, BEV
– + ++ +++ ++
– + ++ +++ ++
12 3 71 M 0 Local OX, FU – – – – – 63 959 2 None SD 120 1059 D IRI, FU,
OX, BEV
+ ++ ++ – +
+ ++ ++ + +




– – – – – 8 49 1 None PD 57 133 D None
– ++ ++ – –
– ++ ++ – –
14 3 (mix) 65 F 2 Dissemi. IRI, OX, FU – – – – – 8 49 1 None PD 50 342 D None
+ + ++ + ++
+ + ++ + ++
15 3 (mix) 71 M 2 Liver, lung IRI, OX, FU – – – – – 8 49 1 None PD 36 102 D None
+ – – +++ ++
+ – – +++ ++
16 3 (mix) 57 M 1 Local none – – ++ – – 38 749 2 None SD 771 1161 D None
+ – – +++ +++
+ ++ – +++ +++
17 3 (mix) 65 M 1 Dissemi. OX, FU – + – +++ – 16 126 2 None PD 69 145 D None
+ + + +++ +
+ + + +++ +
18 3 (mix) 55 F 0 Local IRI, FU – + + – – 8 49 2 None SD 56 56 A Curative
resection
– – + – –
– – + – –




– ++ + – + 8 49 1 None PD 37 52 D None
++ + ++ – +
++ + ++ – +
PS: Eastern Cooperative Oncology Group performance status, LN: lymph nodes, Dessemi: peritoneal dissemination, PFS: progression free survival, OS: over all survival.
IRI: irinotican, OX: oxaliplatin, FU: fluoropyrimidine, RAD: radiation, BEV: bevacizumab, CETU: cetuximab, R: RNF43, T: TOMM34, K: KOC1, R1: VEGFR1, R2: VEGFR2, D: daed, A: alive.



















Table 3 Number of patients responded to each peptide
Dose of
peptide (mg)
Patients R T K R1 R2 Total Average*
n Within 3 courses of vaccinations
0.5 3 2 0 1 1 2 6 2.0
1 3 2 2 1 1 1 7 2.3
3 6 3 4 5 4 3 19 3.2**
3 (cocktail) 6 5 3 4 4 5 21 3.5**
R: RNF43, T: TOMM34, K: KOC1, R1: VEGFR1, R2: VEGFR2.
*: The average numbers of specific CTL induction against each of five peptides per each patient.
**: There was no significant difference to induce the immune responses between the multiple injections of “each peptide” and the single injection of “the peptide
cocktail”. (p=0.694, t-test).
Figure 1 Diagnostic images of case 1 and case 3. (A) T1-weighted magnetic resonance imaging (MRI) of representative radiologic response
to vaccination in case 1 who achieved complete response. (B) Positron Emission Tomography (PET) of case 1. Diffusely infiltrated lymph node
metastases around the hepato-duodenal ligament by MRI (A, left side) as well as PET (B, left side) were confirmed their disappearance by MRI and
PET analysis after 10 months of vaccination (A & B, right side). (C) Computed tomography in case 3 who achieved stable disease. The massive
liver metastases were kept stably for 5 months.
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Figure 2 Kaplan-Meier curves for survival of seventeen vaccinated patients. (A) Overall survival (OS) and progression free survival (PFS) of
seventeen vaccinated patients. (B) Overall survival according to the skin reactions. Local skin reactions at injected site of vaccine were assessed
according to CTCAE grading. (C, D) Overall survival according to the number of peptide specific responses within 3 courses of the vaccination
(C: 2 or more versus 1 or less, D: 3 or more versus 2 or less). (E, F) Overall survival according to the number of peptide specific responses within 6
courses of the vaccination (E: 2 or more versus 1 or less, F: 3 or more versus 2 or less).
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to the numbers of detected peptide specific T cell
responses, strength of T cell responses such as +, ++,
and +++ were evaluated in terms of efficacy of pep-
tide vaccination and clinical outcome, for example, +
versus ++ or more, or, ++ or less versus +++. There
was no significant difference in the clinical outcome ac-
cording to the strength of T cell responses (data not
shown). Serum CEA level before treatment (more than
100 ng/ml or less) was also the predictive marker for
the prognosis of these patients (p = 0.003, data not
shown). Next we performed multivariate analysis of
biomarkers for overall survival using Cox regressionmodel (Table 4). For overall survival, multivariate ana-
lysis indicated that CTL responses to two or more pep-
tides within 3 courses and strong skin reactions at
injected site were significant predictors.
Discussion
We performed phase I study using five novel epitope pep-
tides, including three peptides derived from three oncoan-
tigens as well as two peptides targeting VEGFR1 and
VEGFR2, for colorectal cancer. Vaccinations of five pep-
tides in three different doses as well as cocktail treatment
of five peptides in metastatic CRC patients were well toler-
ated without any severe systemic adverse events. Although
Table 4 Multivariate analysis of biomarkers for overall
survival using Cox regression model
Variable Hazard ratio 95% CI P value
Step 1 CEA: < 100 (ng/ml)
versus ≥100
0.209 0.017 to 2.542 0.220
Local skin reaction:
grade2 versus grade1
0.171 0.013 to 2.190 0.175
CTL response: 2 or
more versus 1 or less
(within 3 courses)
0.078 0.011 to 0.548 0.010
Step 2 Local skin reaction:
garde2 versus garde1
0.048 0.007 to 0.326 0.002
CTL response: 2 or
more versus 1 or less
(within 3 courses)
0.101 0.016 to 0624 0.014
CI, confidence interval.
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they were able to continue the vaccine treatment. Hence,
the safety of our study was confirmed as previous reports
using the same class of peptides [21,22,25].
The average numbers of specific CTL induction
against these five peptides after 12 vaccinations of the
doses of 0.5 mg, 1.0 mg, and 3.0 mg were calculated to
be 2.0, 2.3, and 3.2 peptides/patient, respectively. In this
study, the maximum tolerated dose was not observed.
Moreover, there was no sign of immunosuppression due
to excessive administration at the doses of 3.0 mg. Al-
though the number of the patients enrolled in this study
was very limited, the higher dose of peptide seems to in-
duce peptide-specific CTLs more effectively than the
lower dose. Hence, we would like to the recommended
dose of each peptide for further study to be 3.0 mg.
We also attempted vaccinations of the 5-peptide cock-
tail that was also well tolerated without any serious sys-
temic toxicity. Although there were some concerns that
the mixture of multiple peptides in a single injection
might reduce the immune response due to the different
affinity of each peptide to an HLA molecule, we ob-
served that the average numbers of peptide-specific CTL
inductions per patient was 3.5 within 3 courses of vacci-
nations. Our results demonstrated that the cocktail of
multiple peptides is non-inferiority to the separate injec-
tion of each of multiple peptides. A previous report de-
scribed that the frequency of CTL induction specific to
vaccinated peptides in advanced CRC was approximately
33% [26]. However, we observed the peptide-specific
CTL induction in more than 60% of the patients after
the 12-week of vaccination at the dose of 3.0 mg/week,
indicating that our peptide epitopes might have higher
immunogenicity than peptides used previously.
Among the 18 patients we evaluated clinically, one pa-
tient showed the complete response and six patients
kept stable conditions for 4–7 months. Hence, the re-
sponse rate (RR) was calculated to be 5.6% and thedisease control rate (DCR) to be 38.9%. One review art-
icle reported that the RR of active cancer vaccines for
CRC was 0.9% and the DCR was 11.1% [26]. Hence, our
clinical data has also implied the possible higher im-
munogenicity of our vaccines.
Although our peptide vaccination did not show obvi-
ous superiority in the aspect of RR or DCR, compared
to the worldwide standard therapies for CRC [27,28],
the median overall survival time (MST) of our patients
was 13.5 months which seemed longer than other
presently-available standard therapies; for example, the
MST was 6.1 months and 6.2 months in a phase III trial
of Cetuximab [27] or Panitumumab [28] in patients
with chemotherapy-refractory metastatic CRC, respect-
ively. As US Food and Drug Administration described
in “The guidance for therapeutic cancer vaccine”, this
kind of vaccine treatment usually takes a few to several
months to show clinical benefit due to the time lag to
induce the sufficient number of effecter cells and is ex-
pected to demonstrate delayed effects [24]. The relation
between peptide specific responses and OS was shown
in Figure 2. Patients who revealed the CTL induction
to two or more peptides within 3 courses (MST:
13.5 months) trended to survive longer (P = 0.086) than
patients with CTL induction to one or no peptide
(MST: 3.7 months). Moreover, patients with CTL in-
duction against three or more peptides within 6 courses
of the vaccination (MST: 27.8 months) had significantly
longer survival (P = 0.032) than the remaining patients
(MST: 3.7 months), suggesting the more CTLs were in-
duced, the better prognosis was expected and support-
ing the use of multiple peptides for advanced cancer
patients. Similarly, local reactions at peptides-injected
sites could be possibly a good predictive biomarker(s)
for longer survival; Patients with grade 2 local skin re-
actions at injected site of vaccine survived significantly
(P = 0.001) longer (MST: 29.5 months) than patients
with grade 1 reactions (MST: 4.4 month). These data
suggested that the monitoring of the CTL responses
and the skin reactions might become good predictive
markers during the treatment for the efficacy of vaccin-
ation. Although it is very difficult at present, the prior
selection of patients who are likely to respond well and
induce CTLs effectively to vaccination is also very im-
portant. The presence of a higher number of infiltrated
T cells in tumor microenvironment was suggested as a
predictive biomarker for the response to immunother-
apies and the selection of patients with the better treat-
ment outcome of vaccinations [29].
In conclusion, although the number of patients in this
early-phase trial is very limited, our peptides vaccine
therapy was demonstrated to be safe, effectively induce
peptide-specific immune responses and possibly improve
the prognosis of advanced colorectal cancer. It is certain
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by a much larger double-blind study, we believe that fur-
ther stages of clinical trials should be worth doing.Conclusions
This study indicated that the combination of five novel
peptides can induce strong peptide specific immune re-
sponses in the group who received the dosage of 3.0 mg,
and that the single injection of “the peptide cocktail” is
likely to induce the similar immune responses to the
multiple injections of “each peptide”, and that the overall
survival of patients treated with our peptides was pro-
longed obviously after 6 months from the first vaccin-
ation, which has implied the delayed response of the
vaccination. Moreover, the induction of peptide specific
immune responses had significant relevance to longer
survival. Although we need to verify this preliminary re-
sult by a much larger double-blind study, we believe that
these findings surely lead to the novel therapeutic strat-
egy for advanced colorectal cancer.Additional files
Additional file 1: Figure S1. Positivity of antigen-specific T cell response
was quantitatively defined according to the evaluation tree algorithm. In
brief, the peptide-specific spots (SS) were the average of triplicates by
subtracting the HIV peptide-pulsed stimulator well from the immunized
peptide-pulsed stimulator well. The %SS means the percentage of SS
among the average spots of the immunized peptide pulsed stimulator well.
The positivity of antigen-specific T cell response were classified into four
grades (−, +, ++, and +++) depending on the amounts of peptide-specific
spots and invariability of peptide-specific spots at different responder/
stimulator ratios. SS, peptide-specific spots; R1, responder/stimulator
ratio = 1; R2, responder/stimulator ratio = 0.5; R3, responder/stimulator
ratio = 0.25; R4, responder/stimulator ratio = 0.125.
Additional file 2: Figure S2. Representative immunologic monitoring
assays detecting antigen-specific T-cell responses in patient 10 (A) and 16
(B, C), which were induced interferon-g (IFN-g)-producing cells. Positivity of
antigen-specific T-cell response was quantitatively defined according to the
evaluation tree algorithm (Additional file 1: Figure S1).Abbreviations
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